Illumina, a developer and manufacturer of integrated systems for the analysis of genetic variation and biological functions, completed the acquisition of the remaining 85.5% of GRAIL, a multi-cancer early detection company, from Bristol-Myers Squibb, CPPIB, Sutter Hill Ventures, Celgene Corporation, Johnson & Johnson, ARCH Venture Partners, PSPIB, Hillhouse Capital Management, Decheng Capital, Ally Bridge, 6 Dimensions Capital, McKesson Ventures, Biomatics Capital, Fairview Capital Partners for $8bn. GRAIL stockholders (including Illumina) receive a total consideration of $8bn, consisting of $3.5bn in cash and $4.5bn in shares of Illumina common stock, subject to a collar. "Together, we have an important opportunity to introduce routine and broadly available blood-based screening that enables early cancer detection when treatment can be more effective and less costly. Multi-cancer early detection is better for patients, their physicians, and payors. As we accelerate our path to clinical leadership and the path to multi-cancer early detection, we will continue to drive significant value creation for our stockholders," Francis deSouza, Illumina President and CEO. On August 12, 2021, EU regulators announced they paused the investigation into the deal in light of their request of data from Illumina. On September 21, 2021, EU regulators ordered Illumina to keep Grail as a separate company, while waiting for regulatory clearance of the deal. On October 12, 2021, EU antitrust regulators have resumed their scrutiny of Illumina’s bid for Grail. On January 28, 2021; Illumina moves to allay EU antitrust concerns over $8bn Grail deal.